U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases announces the availability of funding for implementation of the Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21). The purpose of this grant is to foster the development and implementation of interventional exploratory clinical trials aimed at providing clinically-meaningful treatment improvements in symptoms, function, or disease course for patients with rheumatic, musculoskeletal, or skin diseases. Contractors should refer to Section VII, Agency Contacts, in the RFP for information regarding each Institute's grants management contact . . .